200 related articles for article (PubMed ID: 24954113)
1. No increased systemic fibrinolysis in women with heavy menstrual bleeding.
Wiewel-Verschueren S; Knol HM; Lisman T; Bogchelman DH; Kluin-Nelemans JC; van der Zee AG; Mulder AB; Meijer K
J Thromb Haemost; 2014 Sep; 12(9):1488-93. PubMed ID: 24954113
[TBL] [Abstract][Full Text] [Related]
2. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
Szczepaniak P; Zabczyk M; Undas A
PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
[TBL] [Abstract][Full Text] [Related]
3. The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fibrinolytic/inhibitor systems in women with menorrhagia.
Koh SC; Singh K
J Thromb Haemost; 2007 Jan; 5(1):133-8. PubMed ID: 17010149
[TBL] [Abstract][Full Text] [Related]
4. Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.
Cellai AP; Lami D; Magi A; Liotta AA; Rogolino A; Antonucci E; Bandinelli B; Abbate R; Prisco D
Clin Appl Thromb Hemost; 2010 Jun; 16(3):337-44. PubMed ID: 19117964
[TBL] [Abstract][Full Text] [Related]
5. A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects.
Zhou J; Kochan J; Yin O; Warren V; Zamora C; Atiee G; Pav J; Orihashi Y; Vashi V; Dishy V
J Thromb Haemost; 2017 May; 15(5):961-971. PubMed ID: 28211169
[TBL] [Abstract][Full Text] [Related]
6. Elucidating the molecular mechanisms of fibrinolytic shutdown after severe injury: The role of thrombin-activatable fibrinolysis inhibitor.
Coleman JR; Moore EE; Kelher MR; Jones K; Cohen MJ; Banerjee A; Silliman CC
J Trauma Acute Care Surg; 2023 Jun; 94(6):857-862. PubMed ID: 36787438
[TBL] [Abstract][Full Text] [Related]
7. Endometrial fibrinolytic enzymes in women with normal menstruation and dysfunctional uterine bleeding.
Gleeson N; Devitt M; Sheppard BL; Bonnar J
Br J Obstet Gynaecol; 1993 Aug; 100(8):768-71. PubMed ID: 8399019
[TBL] [Abstract][Full Text] [Related]
8. Cyclic changes in endometrial tissue plasminogen activator and plasminogen activator inhibitor type 1 in women with normal menstruation and essential menorrhagia.
Gleeson NC
Am J Obstet Gynecol; 1994 Jul; 171(1):178-83. PubMed ID: 8030696
[TBL] [Abstract][Full Text] [Related]
9. Bidirectional functions of thrombin on fibrinolysis: Evidence of thrombin-dependent enhancement of fibrinolysis provided by spontaneous plasma clot lysis.
Tomczyk M; Suzuki Y; Sano H; Brzoska T; Tanaka H; Urano T
Thromb Res; 2016 Jul; 143():28-33. PubMed ID: 27179129
[TBL] [Abstract][Full Text] [Related]
10. Endometrial haemostasis and menstruation.
Davies J; Kadir RA
Rev Endocr Metab Disord; 2012 Dec; 13(4):289-99. PubMed ID: 23180227
[TBL] [Abstract][Full Text] [Related]
11. Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.
Colucci M; Incampo F; Cannavò A; Menegatti M; Siboni SM; Zaccaria F; Semeraro N; Peyvandi F
J Thromb Haemost; 2016 Aug; 14(8):1603-14. PubMed ID: 27094709
[TBL] [Abstract][Full Text] [Related]
12. Laboratory evaluation of patients with undiagnosed bleeding disorders.
Alves GS; Orsi FA; Santiago-Bassora FD; Quaino SK; Montalvão SA; Paula EV; Annichino-Bizzacchi JM
Blood Coagul Fibrinolysis; 2016 Jul; 27(5):500-5. PubMed ID: 26825625
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolysis in patients with chemotherapy-induced thrombocytopenia and the effect of platelet transfusion.
Heubel-Moenen FCJI; Henskens YMC; Verhezen PWM; Wetzels RJH; Schouten HC; Beckers EAM
J Thromb Haemost; 2019 Jul; 17(7):1073-1084. PubMed ID: 31033178
[TBL] [Abstract][Full Text] [Related]
14. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
Wada T; Gando S; Mizugaki A; Yanagida Y; Jesmin S; Yokota H; Ieko M
Thromb Res; 2013 Jul; 132(1):e64-9. PubMed ID: 23726093
[TBL] [Abstract][Full Text] [Related]
15. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
Soliman M; Osman N; Hefnawy S; El Hawy MA
Pediatr Hematol Oncol; 2022 May; 39(4):318-328. PubMed ID: 34668834
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
Jönsson Rylander AC; Lindgren A; Deinum J; Bergström GM; Böttcher G; Kalies I; Wåhlander K
J Thromb Haemost; 2017 Apr; 15(4):758-769. PubMed ID: 28135035
[TBL] [Abstract][Full Text] [Related]
17. The influence of lower-leg injury and knee arthroscopy on natural anticoagulants and fibrinolysis.
Touw CE; Nemeth B; van Adrichem RA; Schipper IB; Nelissen RGHH; Lisman T; Cannegieter SC
J Thromb Haemost; 2023 Feb; 21(2):227-236. PubMed ID: 36700510
[TBL] [Abstract][Full Text] [Related]
18. The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1.
Whyte CS; Simpson M; Morrow GB; Wallace CA; Mentzer AJ; Knight JC; Shapiro S; Curry N; Bagot CN; Watson H; Cooper JG; Mutch NJ
J Thromb Haemost; 2022 Oct; 20(10):2394-2406. PubMed ID: 35780481
[TBL] [Abstract][Full Text] [Related]
19. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
Morishima Y; Honda Y
J Thromb Thrombolysis; 2019 Jul; 48(1):103-110. PubMed ID: 30972711
[TBL] [Abstract][Full Text] [Related]
20. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
Konieczynska M; Fil K; Bazanek M; Undas A
Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
